Prescription Drug News and Research

RSS

PDI third quarter revenue increases 83% to $36.0 million

PDI, Inc., today reported financial and operational results for the third quarter ended September 30, 2010.

3 Nov 2010

CVS Caremark supports FDA pathway for approval of biogeneric options

CVS Caremark reiterated the company's support that the U.S. Food and Drug Administration (FDA) implement regulations necessary to approve biogeneric drugs under the Affordable Care Act. The company's Senior Vice President of Specialty Pharmacy Operations, Scott Reid, testified before the FDA today during a public hearing to address the development of an approval pathway for biosimilar and interchangeable biological products held at the agency's headquarters in Silver Spring, Maryland.

3 Nov 2010

Positive preliminary data from Protalix's taliglucerase alfa switchover trial for Gaucher disease

Protalix BioTherapeutics, Inc., announced today positive preliminary data from the first 15 patients that completed the Company's nine month, worldwide, multi-center, open-label, switchover trial of taliglucerase alfa for the treatment of Gaucher disease under a protocol cleared by the U.S. Food and Drug Administration (FDA). The data indicate that patients can safely be switched to taliglucerase alfa from imiglucerase (Cerezyme®).

2 Nov 2010

Minn. will accept federal assistance, Tenn. tackles burgeoning drug abuse problem

Politico: "Minnesota will accept federal assistance under the Democrats' health reform law after all, despite Gov. Tim Pawlenty's executive order barring voluntary participation in federal health care programs. The state's Management and Budget Office was one of 700 new organizations that signed up for the Early Retiree Reinsurance Program, a $5 billion program that helps pay for the insurance costs of retirees between the ages of 55 and 64.

2 Nov 2010

NICE to lose its power to ban life saving drugs

Ministers have finally clarified that patients would not be denied life-extending drugs just because the NHS rationing body decides they are too expensive. National Institute for Health and Clinical Excellence (NICE) the drug watchdog in the UK will be stripped of its powers to stop drugs being available on the NHS due to price. The arbitrary limit on the cost of new drugs – around £30,000 per year of extended high-quality life – will be scrapped from 2014.

1 Nov 2010

FDA grants orphan drug designation to Discovery's KL4 surfactant for CF treatment

Discovery Laboratories, Inc. today announced that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis (CF).

1 Nov 2010

Endo third quarter total revenues increase 23% to $444.1 million

Endo Pharmaceuticals today reported financial results for the third quarter 2010.

1 Nov 2010

FDA grants Clinical Data's PRX-8066 Orphan Drug Designation for pulmonary arterial hypertension

Clinical Data, Inc. today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for pulmonary arterial hypertension (PAH) to PRX-8066, the Company's selective serotonin 2B (5-HT2B) receptor antagonist.

1 Nov 2010

BetterRxCard helps McLennan County residents save on prescription drugs

BetterRxCard, the free prescription discount card sponsored by McLennan County, today announced the program has saved $138,562 for McLennan County residents during its initial six months. "Anything we can do to assist in reducing or deferring the costs to our citizens we are glad to participate in," said McLennan County Judge Jim Lewis.

1 Nov 2010

Seven tips for navigating Medicare maze

If you're about to turn 65, you'll be part of the first wave of baby boomers signing up for Medicare. Consumer Reports Health recommends signing up as early as three months ahead of your birthday. Failing to do so could potentially cost you thousands of dollars down the road. That's one of seven tips for navigating the Medicare maze available in the December issue of Consumer Reports and online at www.ConsumerReportsHealth.org.

1 Nov 2010

Humana third quarter diluted EPS increases to $2.32

Humana Inc. today reported diluted earnings per common share (EPS) for the quarter ended September 30, 2010 (3Q10) of $2.32, ahead of management's guidance of $1.65 to $1.75. The company earned $1.78 per share for the quarter ended September 30, 2009 (3Q09).

1 Nov 2010

Research Roundup: Primary care doc pay and satisfaction; fixes to Medicare reimbursements; free vaccines?

A critical element of improving population health in underserved areas is the adequacy and distribution of the primary care physician supply, write the authors of this study, who interviewed 42 primary care physicians from both underserved and non-underserved areas in Los Angeles County, California.

30 Oct 2010

Inadequate payments prompt insurance companies to raise premiums, avoid low-income market

Millions of Medicare recipients have been forcibly reassigned to different prescription drug plans because Part D reimbursements to insurance companies covering low-income patients are lower than the actual costs incurred, according to a study released online today by Health Affairs. The report describes how a system designed to encourage competition and to subsidize care for low-income Medicare patients instead has led companies to raise their premiums in an effort to price themselves out of the low-income segment of the Part D market.

29 Oct 2010

Physicians suggest tips to overcome acute pain

The truth is not all pain is created equal. Acute pain is where it all begins. Lasting for several months, acute pain is typically treated with rest, time and medication. For many, that is enough. But if the pain persists, it converts to chronic pain, and new methods must be explored.

29 Oct 2010

HealthSpring third quarter net income increases 27.1% to $42.3 million

HealthSpring, Inc. today announced its results for the third quarter ended September 30, 2010. Net income of $53.8 million, or $0.95 per diluted share, up 27.1% over $42.3 million, or $0.77 per diluted share, in the 2009 third quarter.

28 Oct 2010

Phrma pushes back against campaign calls for Medicare Part D price negotiation

The powerful pharmaceutical lobby is pushing back against campaign-trail calls to allow Medicare to negotiate drug prices on behalf of millions of seniors enrolled in Part D, The Hill reports.

28 Oct 2010

£600 million cancer drug fund for UK cancer patients

Good news for cancer patients in England, the government has announced that it would fulfill a pledge to set up a drugs fund. Earlier the Department of Health promised the extra funding after a report revealed the low level of spending in the UK on cancer medication compared to the rest of Europe.

27 Oct 2010

US FDA cracks down on importation of unapproved new drugs for personal use

The United States Food and Drug Administration (“FDA”) is cracking down on the importation of unapproved new drugs with regards to personal use. Import Alert #66-41, “Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.” (“IA 66-41”) was most recently published on September 23, 2010. IA 66-41 contains a Red List, a list of importers whose products are automatically detained for FDA violations, of over 400 firms on the charge of importing misbranded unapproved new drugs. Benjamin England, founder of FDAImports.com, LLC and former FDA Compliance Officer, attorney, and Food and Drug Law expert states that “This Import Alert has been expanded to include importers and products of drugs imported strictly for personal use rather than just targeting foreign shippers, which is FDA's normal M.O.”

27 Oct 2010

Upper Peninsula Health Plan awards 3-year PBM contract to Catalyst Rx

Catalyst Rx, the pharmacy benefit management (PBM) subsidiary of Catalyst Health Solutions, Inc. (NASDAQ: CHSI), announced today the award of a three-year PBM contract by the Upper Peninsula Health Plan, a Medicaid Health Care Provider serving the Upper Michigan Counties. The contract covers approximately 38,000 members.

27 Oct 2010

Glaxo to pay $750 million in defective drug settlement

GlaxoSmithKline Plc, one of the world’s largest pharmaceutical companies, has agreed to pay $750 million to settle a U.S. government false-claims lawsuit over the sale of defective drugs. The lawsuit first filed in 2004 by Cheryl D. Eckard, a former global quality assurance manager for the London-based company came to a settlement finally. Eckard, 51, said, “This is not something I wanted to do, but because of patient safety it was necessary.” Being the one to bring this to notice she would receive $96 million from the settlement money. She had warned the company earlier but was fired because of her efforts.

26 Oct 2010